This research study aims to find out the effect of REPOSE, a screening and patient navigation intervention, on the receipt of equitable care among racially and ethnically diverse children with Sleep Disordered Breathing (SDB).

In this study, parents and their child will participate in the REPOSE Patient Navigation Intervention, where the child will be screened for SDB at their pediatric well-visit. If the child's screening is positive, the parent will be asked if they and the child would like to be a part of the REPOSE Patient Navigation Intervention. The REPOSE patient navigation will utilize a patient navigator that will a) ID and address dynamic individual barriers to care, b) provide education and social support for parents and children who are diagnosed with SDB, and c) coordinate care between medical providers and parent/child to complete evidence-based care (e.g., sleep study, tonsillectomy). The navigator will follow patients to completion of recommended treatment or up to 6 months after enrollment.

Patient Navigation has been proven to benefit adult cancer patients but has not been tested in pediatric patients with sleep-disordered breathing. This study is an effort to demonstrate whether patient navigation is effective in increasing the receipt of equitable care for children with SDB. The REPOSE Intervention is designed to guide parents of children with SDB through and around barriers in the complex healthcare system to achieve timely diagnosis and treatment.

The current study will investigate the safety, efficacy and pharmacokinetics of serdexmethylphenidate (SDX) compared to placebo in subjects with Idiopathic Hypersomnia (IH). The study may inform about the best dosing regimen, optimal dose range, duration of treatment, and secondary endpoints for a future Phase 3 study.

The study is designed to look at the usefulness and safety of AXS-12 or placebo for the treatment of Narcolepsy. The open-label treatment period is 24 weeks, which will be followed by a double-blind treatment period of 4 weeks, for a total of up to 28 weeks with 13 visits. Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep. Study staff nor the participants will know if they are receiving a study drug or placebo. Participants will be male or female subjects 15-75 years old with a diagnosis of narcolepsy. Study drug will be administered as a pill.